IRIS
MURDACA, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 17.857
AS - Asia 2.364
NA - Nord America 1.871
SA - Sud America 223
AF - Africa 27
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 22.346
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 17.464
US - Stati Uniti d'America 1.734
SG - Singapore 883
CN - Cina 607
VN - Vietnam 380
BD - Bangladesh 244
FR - Francia 165
BR - Brasile 130
HK - Hong Kong 91
FI - Finlandia 69
DE - Germania 43
AR - Argentina 42
CA - Canada 40
MX - Messico 31
GB - Regno Unito 30
JP - Giappone 25
IQ - Iraq 22
IN - India 21
ID - Indonesia 16
CO - Colombia 13
JM - Giamaica 13
CR - Costa Rica 12
NL - Olanda 12
RU - Federazione Russa 11
ZA - Sudafrica 11
CH - Svizzera 10
IE - Irlanda 10
PH - Filippine 9
PL - Polonia 9
EC - Ecuador 8
ES - Italia 8
HN - Honduras 8
PY - Paraguay 8
TR - Turchia 8
VE - Venezuela 8
MA - Marocco 7
PK - Pakistan 7
TH - Thailandia 7
CL - Cile 6
JO - Giordania 6
MY - Malesia 6
SV - El Salvador 6
TW - Taiwan 5
UZ - Uzbekistan 5
DO - Repubblica Dominicana 4
NI - Nicaragua 4
PR - Porto Rico 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AU - Australia 3
AZ - Azerbaigian 3
BB - Barbados 3
PE - Perù 3
TT - Trinidad e Tobago 3
UA - Ucraina 3
UY - Uruguay 3
BM - Bermuda 2
BO - Bolivia 2
DZ - Algeria 2
EG - Egitto 2
ET - Etiopia 2
GR - Grecia 2
GT - Guatemala 2
IR - Iran 2
KR - Corea 2
KZ - Kazakistan 2
LT - Lituania 2
MD - Moldavia 2
RO - Romania 2
RS - Serbia 2
SA - Arabia Saudita 2
SE - Svezia 2
AI - Anguilla 1
AM - Armenia 1
AT - Austria 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GE - Georgia 1
GP - Guadalupe 1
HR - Croazia 1
KE - Kenya 1
LB - Libano 1
LC - Santa Lucia 1
LV - Lettonia 1
MT - Malta 1
NP - Nepal 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
SC - Seychelles 1
TC - Turks e Caicos 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 22.346
Salva come PNG Salva come JPEG
Città #
Genova 9.464
Genoa 5.071
Rapallo 1.398
Vado Ligure 1.250
San Jose 432
Singapore 420
Ashburn 198
Lauterbourg 155
Beijing 122
Ho Chi Minh City 105
Hanoi 94
Hong Kong 84
New York 84
Council Bluffs 76
Helsinki 66
Bordighera 47
Santa Clara 47
Los Angeles 44
Milan 40
Frankfurt am Main 33
Buffalo 27
Mexico City 21
Orem 21
Rome 20
Tokyo 20
Boardman 19
Haiphong 19
Chicago 18
Dallas 15
Tianjin 15
Charlotte 13
Boston 12
Naples 12
Phoenix 12
St Louis 12
Atlanta 10
Dublin 10
San José 10
Zurich 10
Baghdad 9
Biên Hòa 9
Da Nang 9
Florence 9
Kingston 9
São Paulo 9
Amsterdam 8
London 8
Seattle 8
Bologna 7
Brooklyn 7
Shanghai 7
Amman 6
Bắc Ninh 6
Chennai 6
City of London 6
Johannesburg 6
Miami 6
Montreal 6
Poplar 6
Quảng Ngãi 6
Rio de Janeiro 6
Warsaw 6
Bari 5
Cardiff 5
Catania 5
Des Moines 5
Dhaka 5
Houston 5
Jacksonville 5
Madrid 5
Philadelphia 5
Queens 5
Quận Ba 5
Riverside 5
San Francisco 5
San Salvador 5
Tashkent 5
Toronto 5
Turin 5
Acalanes Ridge 4
Cincinnati 4
Columbus 4
Detroit 4
Figino 4
Guangzhou 4
Kuala Lumpur 4
Las Vegas 4
Managua 4
Omaha 4
Paris 4
Quito 4
Santo Domingo 4
Alma 3
Asunción 3
Baku 3
Bangkok 3
Belo Horizonte 3
Bogotá 3
Bridgetown 3
Cape Town 3
Totale 19.852
Salva come PNG Salva come JPEG
Nome #
Non-antigen-specific CD8(+) T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. 278
Infection risk associated with anti-TNF-α agents: A review 244
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer 232
Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis 230
Autoimmune intrahepatic cholangiopathy associated with antiphospholipid antibody syndrome 229
Characteristics of current heart failure patients admitted to internal medicine vs. cardiology hospital units: the VASCO study 217
Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. 214
Vaccine-preventable infections in Systemic Lupus Erythematosus 206
ACUTE CARDIAC FAILURE AND IGA NEPHROPATHY: AN UNCOMMON SLE ONSET 203
Immunogenicity of infliximab and adalimumab: What is its role in hypersensitivity and modulation of therapeutic efficacy and safety? 202
Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients 200
Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications 196
TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis 196
Adult iatrogenic Cushing's syndrome induced by topical skin corticosteroid misuse 191
The antiphospholipid syndrome: from pathophysiology to treatment 188
Vdelta1 T lymphocytes producing IFN-gamma and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans 187
Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy 185
Treatment Algorithms for Systemic Sclerosis According to Experts 184
Current recommendation to reduce the burden of bacterial and viral infections in patients affected by systemic lupus erythematosus 181
Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis 178
Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis 178
Soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis 176
Remission of Brucella endocarditis in a patient with mitral valve mechanical prosthesis by antibiotic therapy alone: a case report 176
Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: correlation with clinical outcome 176
Immunoregulatory Role of HLA-G in Allergic Diseases 175
A rare hepatic mass in an Italian resident 175
General surgery, translational lymphology and lymphatic surgery 175
Monkeypox 2024 outbreak: Fifty essential questions and answers 175
Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study 174
Soluble HLA-G molecule in patients with perennial allergic rhinitis. 170
Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy 169
Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). 168
Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events 167
Adipokines and sublingual immunotherapy: preliminary report. 166
Body mass index in Th1 and Th2 diseases. 164
Anti-tumour necrosis factor-a treatment with infliximab for disseminated granuloma annulare 164
Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. 163
An Uncommon Presentation of Pancreatic Carcinoma 163
Soluble serum HLA-G and HLA-A, -B, -C molecules in patients with seasonal allergic rhinitis exposed to pollens. 161
Genetic factors and systemic sclerosis 159
A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence 157
Apoptosis in the Homeostasis of the Immune System and in Human Immune Mediated Diseases 157
Effects of antagomiRs on different lung diseases in human, cellular, and animal models 157
HLA-G expression in gastric carcinoma: clinicopathological correlations and prognostic impact 156
Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system’s inhibitor denosumab vs. bisphosphonates 155
Serum vascular endothelial growth factor and sublingual immunotherapy 155
Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults. 155
Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution. 155
Update upon the infection risk in patients receiving TNF alpha inhibitors 155
Hypoadiponectinemia in lipodystrophic HIV individuals: a metabolic marker of subclinical cardiac damage 153
Detection of influenza A(H1N1)pdm09 virus in a patient travelling from Shanghai to Italy in July 2018: An uncommon clinical presentation in a non-seasonal period 153
A case of transposition of the great arteries in a female infant of a HIV-1 infected woman. Potential teratogenic effect of antiretroviral drugs. 153
Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis 152
Endothelial dysfunction in rheumatic autoimmune diseases. 152
Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1 infected patients 149
Plicometer skin test: a new technique for the evaluation of cutaneous involvement in systemic sclerosis. 148
Interleukin-2 therapy in patients with HIV infection 145
Low expression of inhibitory natural killer receptors in CD8 cytotoxic T lymphocytes in long-term non-progressor HIV-1-infected patients 144
Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study 144
Potential use of TNF-α inhibitors in systemic sclerosis. 144
Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. 143
Current views on diagnostic approach and treatment of lymphedema 143
Two year sublingual immunotherapy affects serum leptin 142
Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors. 142
Postexposure HIV prophylaxis regimen. 141
Lymphatic microsurgery to treat lymphedema: techniques and indications for better results. 141
Serum interleukin-17 levels are related to clinical severity in allergic rhinitis 141
Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. 141
Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus 141
Immunogenicity of infliximab and adalimumab 140
Serum adiponectin levels in patients with pollen-induced allergic rhinitis 139
Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis 139
Serum IL-17 after one course of sublingual immunotherapy in allergic rhinitis to birch 139
Role of vitamin d in the clinical course of nasal polyposis 139
Expression of Epidermal Growth Factor receptor (EGFR) in Systemic Sclerosis patients (SSc) and Gastro-oesophageal Reflux Disease (GORD) 138
Accelerated atherosclerosis in patients with Systemic Lupus Erythematosus. 138
Determination of lymphotoxin-α levels in patients with psoriatic arthritis undergoing etanercept treatment 137
Sublingual immunotherapy reduces soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis. 136
Antiphospholipid syndrome and reversible posterior leukoencephalopathy syndrome. 136
Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications 136
Il-33/il-31 axis in immune-mediated and allergic diseases 136
Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current evidences upon safety and immunogenicity 134
Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis 133
Hepatic safety and postexposure prophylaxis 133
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study 132
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART 131
The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases 131
Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity. 131
A compilation answering 50 questions on Monkeypox virus and the current Monkeypox outbreak 131
Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept? 130
Soluble HLA-G serum levels in patients with the Acquired Immunodeficiency Syndrome affected by different AIDS-defining conditions before and after anti-retroviral treatment 129
Differential disappearance of inhibitory natural killer cell receptors during HAART and possible impairment of HIV-1-specific CD8 cytotoxic T lymphocytes. 128
HLA-G Expressing Immune Cells in Immune Mediated Diseases 128
Expression of membrane-bound human leucocyte antigen-G in systemic sclerosis and systemic lupus erythematosus 128
Selective TNF-α inhibitor-induced injection site reactions. 126
Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. 126
Update upon efficacy and safety of TNF-α inhibitors. 124
A machine learning application to predict early lung involvement in scleroderma: A feasibility evaluation 124
Recurrent intestinal perforation associated with thrombosis of inferior vena cava: uncommon presentation of antiphospholipid syndrome. 123
Differential diagnosis in recurrent intestinal perforation: chronic inflammatory disease with intestinal lymphedema or antiphospholipid syndrome? 123
Totale 15.947
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.190
article - articoli 78.190
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 156.380
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.701 43 116 123 190 56 126 78 406 101 154 70 238
2022/20231.671 143 105 28 163 298 285 10 145 261 15 185 33
2023/20241.007 39 149 19 133 66 149 95 80 54 15 63 145
2024/20253.280 111 219 110 236 418 309 363 522 120 152 329 391
2025/20266.625 689 261 565 650 744 535 967 261 430 565 472 486
2026/2027487 487 0 0 0 0 0 0 0 0 0 0 0
Totale 22.822